Tag : SEMAGLUTIDE

CONFERENCE UPDATE

Semaglutide improves walking capacity and QoL in patients with symptomatic PAD and T2D: Results from the phase 3b STRIDE trial
CONFERENCE UPDATE

MASH resolution with no worsening of liver fibrosis demonstrated by semaglutide: Interim results from the phase 3 ESSENCE trial
Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic and progressive liver disease characterized by hepatic steatosis, inflammation, and fibrosis. Despite its high prevalence, effective pharmacological treatments remain limited, with current strategies primarily targeting weight reduction and glycemic control. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has been extensively studied in a broad spectrum of cardiometabolic diseases, positioning it as a potential therapeutic option for MASH.